Oonagh McArdle had always been a healthy, fit, non-smoker so when she began experiencing “strange” symptoms in 2019, she was only mildly concerned, but decided to visit her doctor just in case. Several months and tests later, she received the biggest shock of her life when it was discovered that the strange feeling in her… Read More »
FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of Rybrevant (amivantamab-vmjw) for the… Read More »
Found helpful. Broccoli is a highly antioxidant green vegetable with NRF2-dependent characteristics. Leave a comment Name. Close cart. Eat 4 to 6 small meals a day. Walnuts are a vegetarian source of kung fatty acids. Researchers found that the supplements reduced obstructions in the airway and for be jealth complementary treatment for asthma health. Thank… Read More »
The last thing that Mayra Ramirez remembers from the emergency room at Northwestern Memorial Hospital in Chicago is calling her family to say she had Covid, was about to be put on a ventilator and needed her mother to make medical decisions for her. Ms. Ramirez, 28, did not wake up for more than six… Read More »
It’s been a long road for Bristol-Myers Squibb’s Opdivo, but the immuno-oncology star finally has a place in the lucrative market for previously untreated non-small cell lung cancer. The FDA Friday approved Opdivo alongside fellow BMS checkpoint inhibitor Yervoy for first-line patients whose tumors test positive for biomarker PD-L1, giving patients a chemo-free option and… Read More »
FDA Approves Tabrecta (capmatinib) for Metastatic Non-Small Cell Lung Cancer with METex14 Print this page EAST HANOVER, N.J., May 6, 2020 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that… Read More »